Division of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; University Hospitals Cleveland Medical Center, Case Western Reserve School of Medicine, Cleveland, OH, USA.
Department of Urology, University of Rennes, Rennes, France.
Eur Urol. 2022 Nov;82(5):529-542. doi: 10.1016/j.eururo.2022.08.019. Epub 2022 Sep 10.
International variations in the rates of kidney cancer (KC) are considerable. An understanding of the risk factors for KC development is necessary to generate opportunities to reduce its incidence through prevention and surveillance.
To retrieve and summarize global incidence and mortality rates of KC and risk factors associated with its development, and to describe known familial syndromes and genetic alterations that represent biologic risk factors.
A systematic review was conducted via Medline (PubMed) and Scopus to include meta-analyses, reviews, and original studies regarding renal cell carcinoma, epidemiology, and risk factors.
Our narrative review provides a detailed analysis of KC incidence and mortality, with significant variations across time, geography, and sex. In particular, while KC incidence has continued to increase, mortality models have leveled off. Among the many risk factors, hypertension, obesity, and smoking are the most well established. The emergence of new genetic data coupled with observational data allows for integrated management and surveillance strategies for KC care.
KC incidence and mortality rates vary significantly by geography, sex, and age. Associations of the development of KC with modifiable and fixed risk factors such as obesity, hypertension, smoking, and chronic kidney disease (CKD)/end-stage kidney disease (ESKD) are well described. Recent advances in the genetic characterization of these cancers have led to a better understanding of the germline and somatic mutations that predispose patients to KC development, with potential for identification of therapeutic targets that may improve outcomes for these at-risk patients.
We reviewed evidence on the occurrence of kidney cancer (KC) around the world. Currently, the main avoidable causes are smoking, obesity, and high blood pressure. Although other risk factors also contribute, prevention and treatment of these three factors provide the best opportunities to reduce the risk of developing KC at present.
肾癌(KC)的全球发病率差异很大。了解 KC 发病的危险因素对于通过预防和监测来降低其发病率具有重要意义。
检索并总结全球 KC 的发病率和死亡率以及与其发病相关的危险因素,并描述已知的家族综合征和遗传改变,这些改变代表了生物学危险因素。
通过 Medline(PubMed)和 Scopus 进行系统回顾,包括关于肾细胞癌、流行病学和危险因素的荟萃分析、综述和原始研究。
我们的叙述性综述详细分析了 KC 的发病率和死亡率,其在时间、地理位置和性别上存在显著差异。特别是,虽然 KC 的发病率持续上升,但死亡率模型已经趋于平稳。在众多危险因素中,高血压、肥胖和吸烟是最确定的因素。新的遗传数据的出现加上观察性数据,为 KC 护理的综合管理和监测策略提供了可能。
KC 的发病率和死亡率在地理位置、性别和年龄上存在显著差异。肥胖、高血压、吸烟和慢性肾脏病(CKD)/终末期肾病(ESKD)等可改变和固定危险因素与 KC 发病的相关性已得到很好的描述。这些癌症的遗传特征的最新进展使人们更好地了解了使患者易患 KC 的种系和体细胞突变,为确定可能改善这些高危患者预后的治疗靶点提供了可能。
我们回顾了全球发生肾癌(KC)的证据。目前,可避免的主要原因是吸烟、肥胖和高血压。尽管其他危险因素也有贡献,但预防和治疗这三个因素是目前降低 KC 发病风险的最佳机会。